RBC Europe’s CureVac CVAC Stock Holding History

RBC Europe’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-175	Closed	-$9.56K	–	738
2021 Q3	$9.56K	Hold	175	–	–	﹤0.01%	945
2021 Q2	$12.9K	Hold	175	–	–	﹤0.01%	907
2021 Q1	$16K	Hold	175	–	–	﹤0.01%	822
2020 Q4	$14.2K	Buy	+175	New	+$13.4K	﹤0.01%	806

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

RBC Europe's CVAC Position: Q4 2021 in Review

RBC Europe sold out of CureVac (CVAC) in Q4 2021, closing a stake of 175 shares — an estimated $9.56K sold.

RBC Europe first reported a position in CVAC in Q4 2020 and held it in 4 quarters. The position peaked at $16K in Q1 2021. 103 funds tracked by Wall St. Rank hold CVAC as of Q4 2021.

RBC Europe reported no remaining CureVac position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 175 CureVac shares in Q4 2021, an estimated $9.56K.
RBC Europe first reported a position in CureVac in Q4 2020 and held it in 4 quarters.
RBC Europe's CureVac position peaked at $16K in Q1 2021.
103 funds tracked by Wall St. Rank held CureVac as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.